Minerva Neurosciences, Inc. (NASDAQ:NERV) stock had a weekly volatility of 11.78% and a monthly volatility of 7.24%. Minerva Neurosciences, Inc. NERV shares float stands at 31.40M.
The Barchart Technical Opinion rating is a 72% Buy with a Strongest short term outlook on maintaining the current direction. Longer term, the trend strength is Maximum. Long term indicators mostly agree with the trend.
Recently, Minerva Neurosciences, Inc. (NASDAQ:NERV) reported that Minerva Neurosciences, Inc. quarterly Return on Assets is -24.20%, while quarterly Return on Equity was -30.20%.
The firm’s Total Debt/Equity stood at 0.07 while Long Term Debt/Equity was 0.02.
The firm’s stock 50-Day High is $10.50% and a 50-Day Low of $53.85%. 20-Day Simple Moving Average was $33.02% while 50-Day SMA was $32.57%.
The firm announced EPS of $-0.99. This shows an EPS growth quarter over last quarter was -2.30%. EPS for the year was $14.80% and EPS growth for imminent year is projected to be -0.70%.
The firm’s monthly average volume for the reported quarter was 164.59K and 164.59K for the full fiscal year. The relative volume was 17.47 for the quarter and 17.47 for the full fiscal year.
The stock’s 50-Day High in the last quarter was $10.50% while the 50-Day Low was $53.85%. In the last fiscal year, the stock hit a 52-Week High of $-36.87% and a 52-Week Low of $53.85%.
The firm’s insider ownership was 0.70% and institutional ownership was 87.40%. Total institutional transactions amounted to 2.49%.
Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that it has entered into a binding term sheet to amend its co-development and license agreement with Janssen Pharmaceutica NV (Janssen) related to MIN-202 (JNJ 42827922), a selective orexin-2 receptor antagonist, and to repurchase all Minerva shares owned by Johnson & Johnson Innovation – JJDC, Inc. (an affiliate of Janssen). This amendment and the stock repurchase are conditional upon the closing of the pending acquisition of Actelion Ltd. by affiliates of Janssen and approval by the European Commission.